Defined Contributions Compliance Consultant Loren D. Stark Company (LDSCO)
|
Greenline Wealth Management
|
Pollard & Associates
|
Defined Benefit Combo Cash Balance Compliance Consultant Loren D. Stark Company (LDSCO)
|
Retirement Planners and Administrators (RPA)
|
New York City District Council of Carpenters Benefit Funds
|
Defined Contribution Account Manager Nova 401(k) Associates
|
Great Lakes Pension Associates, Inc.
|
Senior Specialist 401k Recordkeeping T Bank N.A.
|
TPA Retirement Plan Consultant EPIC RPS (TPA/DPS)
|
Fringe Benefit Group
|
Defined Benefit Consultant/Enrolled Actuary Pension Plan Specialists, PC
|
Retirement Solutions Specialists
|
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
The Impact of New Hepatitis C Drugs on National Health Spending
Altarum Institute Dec. 8, 2015
"[T]he huge jump in prescription drug spending that occurred in 2014 was unforeseen. In 2013, spending on prescription drugs grew by only 2.4 percent, but in 2014, it skyrocketed to 12.2 percent. Some of this increase in spending on prescription drugs is due to expanded coverage, and some is due to the acceleration in prescription drug prices. A major source of this growth was the introduction of Sovaldi in December 2013, and Harvoni in October 2014.... U.S. sales of hepatitis C drugs seem to have stabilized at about $14 billion per year, which equates to about 150,000 persons treated per year (at a rate of $90,000 per person treated)."
|
Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |